7 New Breakthrough Pulmonary Fibrosis Treatments In 2025

New Therapies and Treatments In 2025

1. Boehringer Ingelheim’s New-Gen Antifibrotic

A next-generation antifibrotic targeting PDE4B

Slows disease progression with fewer side effects than previous treatments

Currently in Phase III trials, fast-tracked by the FDA

Designed to be taken orally, increasing accessibility

2. Galapagos GLPG1690 (Ziritaxestat)

Targets autotaxin, an enzyme involved in fibrotic signaling

A novel approach beyond current standards like Ofev and Esbriet

Shown to improve lung function metrics in early-stage trials

Under review for use in combination therapies

3. CRISPR-Based Gene Editing Therapies

Cutting-edge trials are exploring genetic correction for inherited PF conditions

Aims to modify mutations at the root of cellular fibrosis

Still in early stages, but 2025 sees the first human safety data emerging

Long-term potential: one-time treatment, disease reversal

4. Inhaled Antifibrotic Formulas

Researchers are trialing inhalable versions of existing drugs, like pirfenidone

Targeted delivery may improve lung concentration with fewer systemic side effects

Ideal for patients who struggle with oral meds or GI sensitivity

Improves day-to-day quality of life for long-term users

5. Anti-Connective Tissue Growth Factor (CTGF) Therapy

CTGF plays a role in scarring and stiffening of lung tissue

New antibodies and biologics are being tested to block this protein

Reduces fibrosis while allowing normal healing to continue

Seen as a promising adjunct to traditional antifibrotics